InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Shoulder Innovations (NYSE: SI) announced the full commercial launch of the InSet™ 70 humeral stem on Sept. 22, 2025 in Grand Rapids, Mich.
The InSet™ 70 expands the company’s I-Series humeral stem line (which began with the InSet™ 95 in 2024), is cleared for both anatomic and reverse shoulder arthroplasty, and addresses indications including osteoarthritis, avascular necrosis, rheumatoid and traumatic arthritis, irreparable cuff tears, and certain revision cases.
Company statements highlight the InSet™ 70’s bone-sparing design, initial fixation comparable to the longer InSet™ 95, simplified surgical workflow, and claimed optimized biomechanics intended to support improved shoulder function for patients.
Shoulder Innovations (NYSE: SI) ha annunciato il lancio commerciale completo del omero InSet™ 70 il 22 settembre 2025 a Grand Rapids, Michigan.
L'InSet™ 70 amplia la linea di stemmi omerali I-Series dell'azienda (iniziata con l'InSet™ 95 nel 2024), è approvato sia per l'artroplastica dell'articolazione della spalla in modo anatomic che inverso, e riguarda indicazioni tra cui osteoartrite, necrosi avascolare, artrite reumatoide e traumatica, rotture irreparabili della cuffia dei rotatori e alcune revisioni.
Le dichiarazioni aziendali evidenziano il design risparmiatore di osso dell'InSet™ 70, una fissazione iniziale comparabile all'InSet™ 95 più lungo, un flusso operativo chirurgico semplificato e una biomeccanica ottimizzata presunta volta a supportare una migliore funzione della spalla per i pazienti.
Shoulder Innovations (NYSE: SI) anunció el lanzamiento comercial completo del vástago humeral InSet™ 70 el 22 de septiembre de 2025 en Grand Rapids, Michigan.
El InSet™ 70 amplía la línea de vástagos humerales I-Series de la empresa (que comenzó con el InSet™ 95 en 2024), está aprobado tanto para artroplastia de hombro anatómica como invertida, y aborda indicaciones que incluyen osteoartritis, necrosis avascular, artritis reumatoide y traumática, desgarros irreparables de la manguita y ciertos casos de revisión.
Las declaraciones de la compañía destacan el diseño que ahorra hueso del InSet™ 70, una fijación inicial comparable al InSet™ 95 más largo, un flujo quirúrgico simplificado y una biomecánica optimizada supuestamente destinada a apoyar una mejor función del hombro para los pacientes.
Shoulder Innovations (NYSE: SI)는 2025년 9월 22일 미시간주 그랜드 래피즈에서 InSet™ 70 상완골 줄기의 완전한 상용 출시를 발표했습니다.
InSet™ 70은 회사의 I-Series 상완골 줄기 라인을 확장하며(2024년의 InSet™ 95로 시작), 해부학적 및 역방향 어깨 관절 성형에 대해 모두 허가되었고, 골관절염, 무혈관성 괴사, 류마티스성 및 외상성 관절염, 회전근개 파열 불가, 특정 재수술 사례를 포함한 적응증을 다룹니다.
회사 성명은 InSet™ 70의 뼈를 덜 차지하는 설계, 더 긴 InSet™ 95와의 초기 고정 비교 가능성, 간소화된 수술 워크플로우, 환자의 어깨 기능 향상을 목표로 하는 최적화된 생체역학이라고 주장합니다.
Shoulder Innovations (NYSE: SI) a annoncé le lancement commercial complet du tige humérale InSet™ 70 le 22 septembre 2025 à Grand Rapids, Michigan.
L'InSet™ 70 étend la ligne de tiges humérales I-Series de l'entreprise (qui a débuté avec l'InSet™ 95 en 2024), est approuvé pour l'arthroplastie de l'épaule anatomique et inversée, et couvre des indications telles que l'arthrose, la nécrose avasculaire, l'arthrite rhumatoïde et traumatique, les déchirures irréparables de la coiffe des rotateurs et certains cas de révision.
Les déclarations de l'entreprise mettent en évidence le design économe en os de l'InSet™ 70, une fixation initiale comparable à celle de l'InSet™ 95 plus long, un flux chirurgical simplifié et une biomécanique optimisée prétendument destinée à soutenir une amélioration de la fonction de l'épaule chez les patients.
Shoulder Innovations (NYSE: SI) kündigte am 22. September 2025 in Grand Rapids, Michigan, den vollständigen kommerziellen Start des InSet™ 70 Humeruskopf-Stamms an.
Der InSet™ 70 erweitert die I-Series-Humerustammlinie des Unternehmens (die 2024 mit dem InSet™ 95 begann), ist sowohl für anatomische als auch für reverse Schulterarthroplastik zugelassen und deckt Indikationen wie Osteoarthritis, avaskuläre Nekrose, rheumatoide und traumatische Arthritis, irreparable Rotatorenmanschetten-Risse und bestimmte Revisionsfälle ab.
Unternehmensangaben heben das knochen-schonende Design des InSet™ 70, eine initiale Fixierung, die mit der längeren InSet™ 95 vergleichbar ist, einen vereinfachten Operationsablauf und eine angeblich optimierte Biomechanik hervor, die darauf abzielt, die Schulterfunktion der Patienten zu verbessern.
شركة Shoulder Innovations (بورصة نيويورك: SI) أعلنت عن الإطلاق التجاري الكامل لعمود الكتف InSet™ 70 في 22 سبتمبر 2025 بجراند رابيدز، ميشيغان.
يمد InSet™ 70 خط عمود الكتف I-Series للشركة (الذي بدأ بـ InSet™ 95 في 2024)، وهو معتمد لكل من الاستبدال الكتفي التركيبي والتجهيزي العكسي، ويغطي مؤشرات تشمل التهاب المفاصل التنكسي، النخر الإقفاري، التهاب المفاصل الروماتويدي والتهاب المفاصل الناتج عن إصابة، تمزقات غير قابلة لإصلاح لكفة الكتف، وبعض حالات التعديل.
وتبرز تصريحات الشركة تصميم InSet™ 70 الحافظ على العظم، والربط الابتدائي الذي يمكن مقارنته مع InSet™ 95 الأطول، وتبسيط سير العمل الجراحي، وادعاء ببيوميكانيكا محسّنة يُفترض أن تدعم وظيفة الكتف لدى المرضى.
- None.
- None.
Insights
Commercial launch of the InSet™ 70 broadens Shoulder Innovations' shoulder arthroplasty offering and may support US revenue growth if adoption follows.
What this does: The full commercial launch of the InSet™ 70 expands the I-Series humeral stem line alongside the existing InSet™ 95. A shorter, bone-sparing stem can address surgeon demand for options across anatomic and reverse shoulder arthroplasty, potentially increasing procedure-level share within the company’s addressable market.
Key dependencies and risks: Adoption depends on surgeon preference, clinical outcomes versus existing stems, inventory and reimbursement pathways, and penetration into high-volume centers. Clinical claims quoted are promotional; real-world fixation and functional benefits must be proven in routine practice to sustain uptake.
Concrete things to watch and timing: Monitor early commercial metrics such as procedure adoption rates, hospital purchasing agreements, and any presented or published outcome data over the next
Expansion of the I-Series Humeral Stem Product Line Further Strengthens Robust Shoulder Arthroplasty Portfolio
"The InSet™ 70 complements our broad portfolio of advanced shoulder implant solutions, and we are excited to bring it to market across
Indicated for use in both anatomic and reverse shoulder arthroplasty, the InSet™ 70 addresses a broad range of clinical needs, including non-inflammatory degenerative joint disease such as osteoarthritis and avascular necrosis, rheumatoid and traumatic arthritis, and correction of functional deformity. In reverse procedures, it is further indicated for irreparable cuff tears with or without arthritis, as well as for revision of other devices when sufficient bone stock remains.
"Featuring the same excellent initial fixation and simple workflow as the longer InSet™ 95, the InSet™ 70 offers the added benefit of bone-sparing utility, making it a compelling offering in the shoulder care space," said Galen Kam, MD. "Essentially, this product affords all the advantages of a larger stem in a smaller, bone-preserving form factor."
"The InSet™ 70 provides my patients with superb humeral fixation within the reverse total shoulder platform, delivering optimized biomechanics and supporting improved shoulder function," said Matthew Pifer, MD.
About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.
Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-announces-full-commercial-launch-of-the-inset-70-humeral-stem-302562301.html
SOURCE Shoulder Innovations
FAQ
What is the InSet™ 70 launched by Shoulder Innovations (NYSE: SI) on Sept. 22, 2025?
How does the InSet™ 70 differ from the InSet™ 95 from 2024?
What clinical indications does the InSet™ 70 cover for SI (NYSE: SI)?
When and where was Shoulder Innovations’ InSet™ 70 announced?
Will the InSet™ 70 be available across the United States immediately?
What benefits did surgeons cite for the InSet™ 70 in the Sept. 22, 2025 announcement?
